

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



創美·CH'MEI

## CHARMACY PHARMACEUTICAL CO., LTD.

### 創美藥業股份有限公司

(A joint stock limited liability company established in the People's Republic of China)

(Stock Code: 2289)

## (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 31 MAY 2021; AND

### (2) DISTRIBUTION OF 2020 FINAL DIVIDEND

References are made to the notice of the annual general meeting of Charmacy Pharmaceutical Co., Ltd. (the "**Company**") dated 27 April 2021 (the "**Notice of AGM**") and the circular of the Company dated 27 April 2021 (the "**Circular**"). Terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

#### (1) Poll Results of the AGM

The Board of the Company is pleased to announce that all the resolutions proposed as set out in the Notice of AGM were duly passed by the Shareholders of the Company by way of poll at the annual general meeting of the Company held on 31 May 2021 (the "**AGM**").

The poll results in respect of all the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Shares Actually Voted (%)		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the report of the board (the " <b>Board</b> ") of directors (the " <b>Directors</b> ") of the Company for the year ended 31 December 2020.	90,208,500 (100%)	0 (0%)	0 (0%)
2.	To consider and, if thought fit, approve the report of supervisory committee of the Company (the " <b>Supervisory Committee</b> ") for the year ended 31 December 2020.	90,208,500 (100%)	0 (0%)	0 (0%)
3.	To consider and, if thought fit, approve the report of the auditors and the audited financial statements of the Company for the year ended 31 December 2020.	90,208,500 (100%)	0 (0%)	0 (0%)

Ordinary Resolutions		Number of Shares Actually Voted (%)		
		For	Against	Abstain
4.	To consider and, if thought fit, approve the re-appointment of SHINEWING Certified Public Accountants (LLP) as the auditors of the Company for the year 2021, to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration.	90,208,500 (100%)	0 (0%)	0 (0%)
5.	To consider and, if thought fit, approve the resolution regarding the election of Directors of the third session of the Board (this resolution is effected by cumulative voting process).			
5.1	election of Mr. Yao Chuanglong as an executive Director of the Company;	90,208,500 (100%)	0 (0%)	0 (0%)
5.2	election of Ms. Zheng Yuyan as an executive Director of the Company;	90,208,500 (100%)	0 (0%)	0 (0%)
5.3	election of Mr. Lin Zhixiong as an executive Director of the Company;	90,208,500 (100%)	0 (0%)	0 (0%)
5.4	election of Mr. Li Weisheng as a non-executive Director of the Company;	90,208,500 (100%)	0 (0%)	0 (0%)
5.5	election of Mr. Wan Chi Wai Anthony as an independent non-executive Director of the Company;	90,208,500 (100%)	0 (0%)	0 (0%)
5.6	election of Mr. Zhou Tao as an independent non-executive Director of the Company; and	90,208,500 (100%)	0 (0%)	0 (0%)
5.7	election of Mr. Guan Jian (also known as Guan Suzhe) as an independent non-executive Director of the Company.	90,208,500 (100%)	0 (0%)	0 (0%)
6.	To consider and, if thought fit, approve the resolution regarding the election of the Shareholder Representative Supervisor and the Independent Supervisor of the third session of the Supervisory Committee (this resolution is effected by cumulative voting process).			
6.1	election of Ms. Zhang Ling as the Independent Supervisor of the third session of the Supervisory Committee; and	90,208,500 (100%)	0 (0%)	0 (0%)
6.2	election of Mr. Lin Zhijie as the Shareholder Representative Supervisor of the third session of the Supervisory Committee.	90,208,500 (100%)	0 (0%)	0 (0%)
7.	To consider and, if thought fit, approve the resolution regarding the remuneration of the Directors and Supervisors of the Company.	90,208,500 (100%)	0 (0%)	0 (0%)
8.	To consider and, if thought fit, approve the Company's profit distribution plan and declaration of final dividends for the year ended 31 December 2020.	90,208,500 (100%)	0 (0%)	0 (0%)

Ordinary Resolutions		Number of Shares Actually Voted (%)		
		For	Against	Abstain
9.	To consider and, if thought fit, approve the projected daily related transactions of the Company in 2021.	82,302,000 (100%)	0 (0%)	0 (0%)
10.	To consider and, if thought fit, approve the Company and its subsidiaries (the " <b>Group</b> ") application for a comprehensive credit line of no more than RMB1.8 billion from banks in 2021, with a credit period of one year. Such credit line is reusable. The variety of the comprehensive credit line includes but is not limited to short-term working capital loans, long-term borrowings, bank acceptance bills, commercial acceptance bills, letters of guarantee, letters of credit, mortgage loans and pledge loan. The Chairman is authorised to represent the Group in completing relevant procedures within the comprehensive credit line approved by the bank and to sign all the legal documents during the period from the date when this proposal is passed at the AGM to the end of the next annual general meeting, such as contracts, agreements and proofs, relating to credit products including but not limited to loans, credits, trusts and finance leases.	90,208,500 (100%)	0 (0%)	0 (0%)
11.	To consider and, if thought fit, approve the Company and its subsidiaries (the " <b>Group</b> ") to provide support (includes but not limited to pledge, charge, guarantee and trust support) for financing matters of the Group in 2021, as long as the aggregate amount does not exceed RMB 1.8 billion, includes but not limited to loans, credits, trust and finance leases. The chairman is authorised to represent the Group in completing relevant procedures within the approved support limit, during the period from the date when this proposal is passed at the AGM to the end of the next annual general meeting, and to sign all the legal documents such as contracts, agreements, certificates and other legal documents related to financing for the Group (including but not limited to loan, facility, trust, financial leasing, and etc.) .	90,208,500 (100%)	0 (0%)	0 (0%)
Special Resolutions		Number of Shares Actually Voted (%)		
		For	Against	Abstain
12.	To consider and, if thought fit, approve the proposed amendments to the articles of association of the Company (the " <b>Articles of Association</b> ") (details of which are set out in the circular of the Company dated 27 April 2021), and that any Director be and is hereby authorised to modify the wordings of such amendments as appropriate (such amendments will not be required to be approved by the shareholders of the Company) and execute all such documents and/or do all such acts as the Directors may, in their absolute discretion, deem necessary or expedient and in the interest of the Company in order to deal with other related issues arising from the amendments to the Articles of Association of the Company.	90,208,500 (100%)	0 (0%)	0 (0%)

Special Resolutions		Number of Shares Actually Voted (%)		
		For	Against	Abstain
13.	To grant a general mandate to the Board to allot, issue and deal with additional domestic shares not exceeding 20% of the domestic shares of the Company in issue and additional H shares not exceeding 20% of the H shares of the Company in issue and authorise the Board to make corresponding amendments to the Articles of Association as it thinks fit so as to reflect the new capital structure upon the allotment or issuance of shares.	90,208,500 (100%)	0 (0%)	0 (0%)

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 11, these resolutions were duly passed as ordinary resolutions of the Company.

As more than two-thirds of the votes were cast in favour of the resolutions numbered 12 and 13, these resolutions were duly passed as special resolutions of the Company.

**Notes:**

- As at the date of the AGM, the total number of issued Shares was 108,000,000 Shares, comprising 28,000,000 H Shares and 80,000,000 Domestic Shares, which represented the total number of shares entitling the holders to attend and vote on the proposed resolutions (save for resolution numbered 9) at the AGM.
- Guangzhou Pharmaceutical Baiyunshan Hong Kong Company Limited (廣藥白雲山香港有限公司) held 7,906,500 H Shares, representing 7.32% of the issued share capital of the Company as at the date of the AGM. As disclosed in the Circular, pursuant to the Rules Governing the Listing of Shares on the Shenzhen Stock Exchange, the above company shall abstain from voting in relation to the ordinary resolution numbered 9. Hence, a total of 82,302,000 Shares will entitle their holders to vote for or against the ordinary resolution numbered 9 at the AGM. Save as disclosed above, there were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the AGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.
- None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.
- For the above resolutions (save for resolution numbered 9), the Shareholders, proxies or authorised representatives holding in aggregate of 90,208,500 Shares, representing approximately 83.53% of the total voting Shares, were present in person or by proxy at the AGM.
- Pursuant to the Listing Rules, SHINEWING Certified Public Accountants (LLP), the auditors of the Company for the year 2020, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

## (2) DISTRIBUTION OF 2020 FINAL DIVIDEND

### Information on Distribution of 2020 Final Dividend

The Board announces the following information relating to the distribution of 2020 final dividend:

The Company will distribute the final dividend of RMB0.20 (tax inclusive) per Share for the year ended 31 December 2020 (the "**2020 Final Dividend**") to the Shareholders whose names appear on the register of members of the Company on Wednesday, 9 June 2021. The 2020 Final Dividend amounts to an aggregate of RMB21.6 million (tax inclusive), in which the dividend of Domestic

Shares amounts to RMB16 million (tax inclusive) and the dividend of H Shares amounts to RMB5.6 million (tax inclusive). For distribution of the 2020 Final Dividend, dividends on Domestic Shares shall be paid in Renminbi and dividends on H Shares shall be paid in Hong Kong Dollars at the average medium price of the related foreign exchange rate as announced by the People's Bank of China for a calendar week immediately prior to the date of AGM. The average medium price of Renminbi against Hong Kong Dollar published by The People's Bank of China for a calendar week immediately prior to the AGM, that was, from Monday, 24 May 2021 to Sunday, 30 May 2021, was HK\$1.00 to RMB0.826180. Accordingly, the 2020 Final Dividend payable per H Share is HK\$0.242078(tax inclusive). The Company has appointed Computershare Hong Kong Trustees Limited as the receiving agent (the "**Receiving Agent**") in Hong Kong which will receive the 2020 Final Dividend declared by the Company on behalf of the holders of H Shares. The 2020 Final Dividend will be paid by the Receiving Agent and the dividend warrants will be posted by the H share registrar of the Company, Computershare Hong Kong Investor Services Limited, by ordinary mail to holders of H Shares who are entitled to receive the 2020 Final Dividend at their own risks on or before Thursday, 15 July 2021.

### **Withholding of Income Taxes on Dividend Income**

As disclosed in the Circular, pursuant to the Corporate Income Tax Law of the PRC and its implementation rules and relevant regulations including Guo Shui Han [2008] No. 897 issued by China's State Administration of Taxation, where the Company distributes the 2020 Final Dividend to non-resident enterprise Shareholders whose names appear on the register of members for H Shares, it is obliged to withhold corporate income tax at the tax rate of 10%. Any H Shares registered in the name of non-individual registered Shareholders, including HKSCC Nominees Limited, other nominees or trustees, or other organisations or groups, will be treated as Shares being held by non-resident enterprise Shareholders, and consequently the dividends received will be subject to the withholding of the corporate income tax.

Pursuant to the PRC Individual Income Tax Law and its implementation regulations and relevant regulations including Guo Shui Han [2011] No. 348 issued by China's State Administration of Taxation, the Company is required to withhold non-resident individual income tax for non-resident individual Shareholders of H Shares. The overseas resident individual Shareholders who hold the shares issued in Hong Kong by the domestic nonforeign-invested enterprises are entitled to relevant tax concessions pursuant to the provisions in the tax treaties between the country(ies) in which they are domiciled and the PRC, and the tax arrangements between the Mainland and Hong Kong or Macau. As for the individual Shareholders of H Shares, the Company will generally withhold the individual income tax of the dividends at the tax rate of 10%, except for the other requirements of the tax regulations and relevant tax treaties.

By order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yao Chuanglong**  
*Chairman*

Shantou, the PRC, 31 May 2021

*As at the date of this announcement, the executive Directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Mr. Lin Zhixiong; the non-executive Director of the Company is Mr. Li Weisheng; and the independent non-executive Directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).*